Paushak Limited has announced significant leadership changes following its Board meeting held on March 10, 2026. The company disclosed key directorial appointments and resignations under Regulation 30 of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Leadership Transition Details

The Board meeting, which commenced at 4:30 p.m. and concluded at 4:50 p.m., addressed two major personnel changes that will reshape the company's executive structure.

New Appointment Approved

Based on recommendations from the Nomination and Remuneration Committee, the Board approved a strategic appointment to fill the leadership void.

Professional Background of New Appointee

Mr. Jain Parkash brings extensive industry experience to his new role. His educational qualifications include:

• Bachelor of Engineering (B.E.) in Industrial Engineering with Honours from Thapar University, Patiala
• Post Graduate Diploma in Human Resources Development from National Institute of Human Resources Development
• Diploma in Management from IGNOU

His professional experience spans over 30 years in specialty chemicals, agro-chemicals, and pharmaceutical API/intermediates. He has previously been associated with Punjab Chemicals & Crop Protection Limited and Tagros Chemicals India Private Limited. Additionally, Mr. Jain Parkash serves as a Non-Executive Director on the Board of Alembic Limited.

Regulatory Compliance and Documentation

The company has confirmed that Mr. Jain Parkash is not debarred from holding directorship by any SEBI order or other regulatory authority. He is not related to any existing Directors or Key Managerial Personnel of the company. Paushak Limited will seek shareholders' approval for the appointment through appropriate resolutions in due course.

Resignation Confirmation

Mr. Chintan Gosaliya's resignation letter, dated March 10, 2026, confirmed no material reasons beyond career advancement for his departure. The Board accepted his resignation during the meeting, and the company will file requisite e-forms with the Ministry of Corporate Affairs as per regulatory requirements. The detailed disclosure has been provided in accordance with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Paushak Limited has announced its unaudited financial results for the third quarter of FY26 ended December 31, 2025, showing mixed performance with revenue growth but declining profitability. The Gujarat-based specialty chemicals company's Board of Directors approved the results at a meeting held on January 27, 2026.

Financial Performance Overview

The company's quarterly performance presents a contrasting picture of top-line growth and bottom-line pressure:

Nine-Month Performance Analysis

For the nine-month period ended December 31, 2025, Paushak demonstrated resilience in revenue generation while facing profitability challenges:

Cost Structure and Operational Metrics

The company's expense analysis reveals several key trends affecting profitability. Employee benefits expense increased to ₹1,090 lacs in Q3FY26 from ₹932 lacs in Q3FY25, partly due to additional provisions of ₹101.07 lacs related to new Labour Codes implemented by the Government of India on November 21, 2025. Cost of materials consumed rose to ₹1,198 lacs from ₹976 lacs in the corresponding quarter last year.

Corporate Actions and Structural Changes

Paushak undertook significant corporate restructuring during the period. The company's authorized share capital was reclassified to ₹20 crore divided into 4 crore equity shares of ₹5 each. A major bonus issue was executed with 1,84,92,684 equity shares allotted in a 3:1 ratio on October 6, 2025. The paid-up equity share capital increased substantially to ₹1,233 lacs from ₹308 lacs in the previous year.

Market Expansion and Listing

The company achieved a significant milestone with its equity shares getting listed on the National Stock Exchange of India Limited effective December 1, 2025. This dual listing on both BSE and NSE enhances the company's market accessibility and liquidity for investors. The Board of Directors had approved the NSE listing proposal at their meeting held on October 9, 2025.

Regulatory Compliance and Outlook

The financial results were reviewed by statutory auditors CNK & Associates LLP and approved by the Board of Directors. The company operates exclusively in the specialty chemicals business, maintaining focus on its core competency. The implementation of new Labour Codes represents an ongoing regulatory adaptation that the company is managing through appropriate provisioning mechanisms.